CD68 as a multi-omic prognostic biomarker in digestive system cancers: correlations with tumor-infiltrating immune cells and immune checkpoints
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.CD68 expression varies across digestive cancers. High CD68 protein levels indicate a good prognosis in colorectal and stomach cancers, correlating with immune cells and checkpoints.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- CD68 is key for phagocytosis but its role in digestive system cancers (DSC) is unclear.
- Understanding CD68's expression, prognostic value, and immune correlations in DSC is crucial.
Purpose Of The Study
- To investigate CD68 expression levels in DSC.
- To evaluate the prognostic significance of CD68 in DSC.
- To analyze correlations between CD68, tumor-infiltrating immune cells (TIICs), and tumor immune checkpoints (TICs) in DSC.
Main Methods
- Analyzed CD68 mRNA and protein expression using online databases and immunohistochemistry (IHC).
- Assessed prognostic value via overall survival (OS) analysis.
- Correlated CD68 with six TIICs and four TICs using the Tumor Immune Estimation Resource (TIMER).
Main Results
- CD68 mRNA was upregulated in esophageal carcinoma (ESCA) and stomach adenocarcinoma (STAD), but downregulated in colon adenocarcinoma (COAD), liver hepatocellular carcinoma (LIHC), and pancreas invasive ductal carcinoma (PAAD).
- CD68 protein was upregulated in COAD but downregulated in ESCA, LIHC, PAAD, and STAD compared to normal tissues.
- CD68 protein expression was a significant prognostic marker in COAD and STAD, correlating positively with TIICs and TICs.
Conclusions
- CD68 is a potential prognostic biomarker in COAD and STAD.
- CD68 may be a valuable target for diagnosis, prognosis, and therapy in DSC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.